Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling.
The purpose of the investigation was to test the use of alendronate in the therapy of children affected by chronic rheumatic diseases and symptomatic drug-induced osteoporosis. Two courses of alendronate were intravenously administered to four girls with vertebral fractures that were glucocorticoid induced. Improvement of back pain and bone mineral density increase evaluated by DXA and conventional spine X-rays were observed. Our study supports the ABD-induced improvement of the negative effects of long-term therapy on bone mineral density in children with chronic rheumatic diseases.
Falcini
F
F
Department of Pediatrics, University of Florence Medical School, Italy.
Trapani
S
S
Ermini
M
M
Brandi
M L
ML
D000293:Adolescent; D019386:Alendronate / Q000008:administration & dosage*; D015519:Bone Density; D016723:Bone Remodeling / Q000187:drug effects*; D002648:Child; D005260:Female; D005938:Glucocorticoids / Q000037:antagonists & inhibitors*; D006801:Humans; D007275:Injections, Intravenous; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000473:pathology; D011859:Radiography; D012216:Rheumatic Diseases / Q000188:drug therapy; D013131:Spine / Q000000981:diagnostic imaging / Q000473:pathology
D005938:Glucocorticoids; D019386:Alendronate